A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT06235229
Phase
PHASE1 / PHASE2
Sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • GC012F
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Hangzhou, China|30.29365,120.16142
  • Jinan, China|36.66833,116.99722
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients must have a diagnosis of active multiple myeloma as defined by the updated IMWG (International Myeloma Working Group) criteria, and meet o…
  • Serum M protein ≥ 1 g/dL;
  • Urine M protein ≥ 200 mg/24hrs;
  • Serum free light chain (sFLC) ≥ 10 mg/dL with abnormal sFLC κ/λ ratio.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →